CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
The studies on CBD for headache pain are still in their infancy, but with promising results so far. A 2017 study published in the Cannabis and Cannabinoid Research Journal worked with 26 people who were experiencing rebound headaches. The pain management results were better for the cannabis-nabilone formula over either ibuprofen or nabilone alone. (As a nerdy side note, the article is a great read if you’re interested in the history of cannabis as a pain reliever.)
Vape Pens – Perhaps the easiest way to get the CBD Oil into your body is through a vape pen. A vape pen is about the size of an ink pen but has a CBD oil cartridge with a heating element. Many people like vape pens because there is very little in the way of odor after using it and it allows for a lot of discretion because it can be pulled out of your pocket and used on demand.